GT Biopharma (GTBP) Other Non-Current Liabilities (2014 - 2024)
GT Biopharma (GTBP) posted quarterly Other Non-Current Liabilities of $277000.0 for Q2 2024, down 81.99% year-over-year from $1.5 million in Q3 2023, and down 29.7% quarter-over-quarter from $394000.0 in Q1 2024.
GT Biopharma (GTBP) Other Non-Current Liabilities (2014 - 2024) Analysis & Trends
GT Biopharma (GTBP) has reported Other Non-Current Liabilities for 6 consecutive years, with $277000.0 the latest figure, recorded in Q2 2024.
- In Q2 2024, Other Non-Current Liabilities fell 81.99% year-over-year to $277000.0; the TTM figure through Jun 2024 stood at $277000.0 (down 81.99% YoY), while the FY2023 annual figure was $1.1 million, up 5436.84% from the prior year.
- Other Non-Current Liabilities slipped to $277000.0 in Q2 2024 per GTBP's latest filing, from $394000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $2.9 million in Q1 2023 and bottomed at $19000.0 in Q4 2022.
- Historically, Other Non-Current Liabilities has averaged $1.0 million across 3 years, with a median of $1.1 million in 2023.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities jumped 5436.84% — and 2024, when it sank 86.53%.
- GT Biopharma's Other Non-Current Liabilities stood at $19000.0 in 2022, then surged by 5436.84% to $1.1 million in 2023, then sank by 73.67% to $277000.0 in 2024.
- Business Quant data shows GTBP's Other Non-Current Liabilities at $277000.0 in Q2 2024, $394000.0 in Q1 2024, and $1.1 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 277,000.00 |
| Mar 31, 2024 | 394,000.00 |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 1.54 Mn |
| Mar 31, 2023 | 2.93 Mn |
| Dec 31, 2022 | 19,000.00 |
| Mar 31, 2016 | 4.80 Mn |
| Dec 31, 2015 | 33.27 Mn |
| Mar 31, 2014 | 214,000.00 |